MannKind Corporation (NASDAQ:MNKD) won FDA clearance for Furoscix ReadyFlow autoinjector for at‑home furosemide with urine output matching IV, advanced a nintedanib DPI from INFLO‑1 into global Phase 2 after strong Phase 1b safety, set Q2 results and call for Aug 5, and drew a Wells Fargo price target raise to $14.
Previous Week Recap
- Furoscix ReadyFlow Cleared for At-Home Use: MannKind (MNKD) won FDA clearance for Furoscix ReadyFlow autoinjector for at-home furosemide in U.S. heart‑failure/kidney patients; urine output matched IV; company plans U.S. sales by end of August.
- MNKD Q2 2026 Results Data: MannKind (MNKD) will report Q2 2026 results after market close on Aug 5, 2026, and hold a 4:30 p.m. ET earnings call; webcast and ~90-day replay on company site.
- INFLO-1 Phase 1b Meets Primary Goal: MannKind (MNKD) reported Phase 1b INFLO-1: nintedanib DPI met primary goal, showed strong safety/tolerability, no serious AEs or GI effects, efficient lung delivery; global Phase 2 underway.
- Wells Fargo Boosts MNKD Target: Wells Fargo raised MannKind (MNKD) price target from $11.00 to $14.00 per share; no timing, rationale, or analyst rating details were provided.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.